Antithymocyte Globulin Induction Therapy in Hepatitis C–Positive Liver Transplant Recipients
It is unclear whether antithymocyte globulin (ATG) induction therapy in hepatitis C–positive (HCV-positive) liver transplant recipients influences the risk of developing recurrent HCV disease. Multiple acute rejection episodes and high-dose steroids and/or OKT3 used to treat acute rejection increase...
Gespeichert in:
| Veröffentlicht in: | Journal of gastrointestinal surgery 2005-09, Vol.9 (7), p.896-902 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 902 |
|---|---|
| container_issue | 7 |
| container_start_page | 896 |
| container_title | Journal of gastrointestinal surgery |
| container_volume | 9 |
| creator | Horton, Peter J. Tchervenkov, Jean Barkun, Jeff S. Rochon, Caroline Chaudhury, Prosanto K. Znajda, Tammy L. Martinie, John B. Metrakos, Peter |
| description | It is unclear whether antithymocyte globulin (ATG) induction therapy in hepatitis C–positive (HCV-positive) liver transplant recipients influences the risk of developing recurrent HCV disease. Multiple acute rejection episodes and high-dose steroids and/or OKT3 used to treat acute rejection increase the risk of graft loss from HCV. We studied the impact of ATG induction on graft and patient survival in HCV-positive liver transplants performed since 1990. Recipients who died or lost their grafts within 1 month of transplantation were excluded. Second, third, and fourth grafts were excluded, as were patients with stage III or IV hepatocellular carcinoma. There were 443 cadaveric liver transplants in adult recipients, of whom 142 (32%) were HCV positive. The incidence of biopsy-proven acute rejection was less in patients who received ATG induction, 34.2% (ATG induction) versus 66.6% (no ATG induction) (
P ≤ .01). ATG induction did not influence the risk of graft loss from HCV-related disease (
P
=
.75). When only HCV-related graft loss was considered, 10-year graft survival for HCV-positive recipients was 74% (ATG induction) versus 68.2% (no ATG induction). Whether ATG induction was given or not had no significant impact on either overall graft survival (
P
=
.39) or patient survival (
P
=
.11) in HCV-positive recipients. |
| doi_str_mv | 10.1016/j.gassur.2005.06.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68550056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1091255X05005378</els_id><sourcerecordid>68550056</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-210ea03b10d8b6f9ea4d7a8b9bba748832e571f9083c632cf9a97204f6b9a4503</originalsourceid><addsrcrecordid>eNp9kM1q3DAQgEVoyF_7BiEYCr3ZHUm2LF8CYWl-YKGhbKGnClkeJ1q8liPJgb31HfKGeZIq7EIhh-owGoZvfvgIOadQUKDi67p40CHMvmAAVQGiAAYH5ITKmuelYOJDyqGhOauqX8fkNIQ1AK2ByiNyTAXldSXpCfl9NUYbH7cbZ7YRs5vBtfNgx-xu7GYTrRuz1SN6PW2zVLzFSSfahmzx-ufl3oWUP2O2TMFnK6_HMA16jNkPNHayOMbwkRz2egj4af-fkZ_X31aL23z5_eZucbXMDZcy5owCauAthU62om9Ql12tZdu0ra5LKTnDqqZ9A5IbwZnpG93UDMpetI0uK-Bn5Mtu7uTd04whqo0NBod0Dro5KCGrKmkSCfz8Dly72Y_pNkUpZYzX6SWq3FHGuxA89mrydqP9VlFQb_bVWu3sqzf7CoRK9lPbxX743G6w-9e0152Ayx2AycWzRa-CSZ4Mdtajiapz9v8b_gIFtZlY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112237777</pqid></control><display><type>article</type><title>Antithymocyte Globulin Induction Therapy in Hepatitis C–Positive Liver Transplant Recipients</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Alma/SFX Local Collection</source><creator>Horton, Peter J. ; Tchervenkov, Jean ; Barkun, Jeff S. ; Rochon, Caroline ; Chaudhury, Prosanto K. ; Znajda, Tammy L. ; Martinie, John B. ; Metrakos, Peter</creator><creatorcontrib>Horton, Peter J. ; Tchervenkov, Jean ; Barkun, Jeff S. ; Rochon, Caroline ; Chaudhury, Prosanto K. ; Znajda, Tammy L. ; Martinie, John B. ; Metrakos, Peter</creatorcontrib><description>It is unclear whether antithymocyte globulin (ATG) induction therapy in hepatitis C–positive (HCV-positive) liver transplant recipients influences the risk of developing recurrent HCV disease. Multiple acute rejection episodes and high-dose steroids and/or OKT3 used to treat acute rejection increase the risk of graft loss from HCV. We studied the impact of ATG induction on graft and patient survival in HCV-positive liver transplants performed since 1990. Recipients who died or lost their grafts within 1 month of transplantation were excluded. Second, third, and fourth grafts were excluded, as were patients with stage III or IV hepatocellular carcinoma. There were 443 cadaveric liver transplants in adult recipients, of whom 142 (32%) were HCV positive. The incidence of biopsy-proven acute rejection was less in patients who received ATG induction, 34.2% (ATG induction) versus 66.6% (no ATG induction) (
P ≤ .01). ATG induction did not influence the risk of graft loss from HCV-related disease (
P
=
.75). When only HCV-related graft loss was considered, 10-year graft survival for HCV-positive recipients was 74% (ATG induction) versus 68.2% (no ATG induction). Whether ATG induction was given or not had no significant impact on either overall graft survival (
P
=
.39) or patient survival (
P
=
.11) in HCV-positive recipients.</description><identifier>ISSN: 1091-255X</identifier><identifier>EISSN: 1873-4626</identifier><identifier>DOI: 10.1016/j.gassur.2005.06.020</identifier><identifier>PMID: 16137581</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Alcohol Drinking ; Antilymphocyte serum ; Antilymphocyte Serum - therapeutic use ; Cadaver ; Cause of Death ; Cytomegalovirus Infections - complications ; Female ; Follow-Up Studies ; Graft Rejection - etiology ; Graft Survival ; Hepatitis B - complications ; hepatitis C ; Hepatitis C - complications ; Humans ; immunosuppressive agents ; Immunosuppressive Agents - therapeutic use ; Liver ; Liver Transplantation ; Male ; Middle Aged ; Recurrence ; Risk Factors ; Survival Rate ; Transplants & implants ; Treatment Outcome</subject><ispartof>Journal of gastrointestinal surgery, 2005-09, Vol.9 (7), p.896-902</ispartof><rights>2005 The Society for Surgery of the Alimentary Tract</rights><rights>The Society for Surgery of the Alimentary Tract, Inc. 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-210ea03b10d8b6f9ea4d7a8b9bba748832e571f9083c632cf9a97204f6b9a4503</citedby><cites>FETCH-LOGICAL-c388t-210ea03b10d8b6f9ea4d7a8b9bba748832e571f9083c632cf9a97204f6b9a4503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16137581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Horton, Peter J.</creatorcontrib><creatorcontrib>Tchervenkov, Jean</creatorcontrib><creatorcontrib>Barkun, Jeff S.</creatorcontrib><creatorcontrib>Rochon, Caroline</creatorcontrib><creatorcontrib>Chaudhury, Prosanto K.</creatorcontrib><creatorcontrib>Znajda, Tammy L.</creatorcontrib><creatorcontrib>Martinie, John B.</creatorcontrib><creatorcontrib>Metrakos, Peter</creatorcontrib><title>Antithymocyte Globulin Induction Therapy in Hepatitis C–Positive Liver Transplant Recipients</title><title>Journal of gastrointestinal surgery</title><addtitle>J Gastrointest Surg</addtitle><description>It is unclear whether antithymocyte globulin (ATG) induction therapy in hepatitis C–positive (HCV-positive) liver transplant recipients influences the risk of developing recurrent HCV disease. Multiple acute rejection episodes and high-dose steroids and/or OKT3 used to treat acute rejection increase the risk of graft loss from HCV. We studied the impact of ATG induction on graft and patient survival in HCV-positive liver transplants performed since 1990. Recipients who died or lost their grafts within 1 month of transplantation were excluded. Second, third, and fourth grafts were excluded, as were patients with stage III or IV hepatocellular carcinoma. There were 443 cadaveric liver transplants in adult recipients, of whom 142 (32%) were HCV positive. The incidence of biopsy-proven acute rejection was less in patients who received ATG induction, 34.2% (ATG induction) versus 66.6% (no ATG induction) (
P ≤ .01). ATG induction did not influence the risk of graft loss from HCV-related disease (
P
=
.75). When only HCV-related graft loss was considered, 10-year graft survival for HCV-positive recipients was 74% (ATG induction) versus 68.2% (no ATG induction). Whether ATG induction was given or not had no significant impact on either overall graft survival (
P
=
.39) or patient survival (
P
=
.11) in HCV-positive recipients.</description><subject>Adult</subject><subject>Aged</subject><subject>Alcohol Drinking</subject><subject>Antilymphocyte serum</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Cadaver</subject><subject>Cause of Death</subject><subject>Cytomegalovirus Infections - complications</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft Rejection - etiology</subject><subject>Graft Survival</subject><subject>Hepatitis B - complications</subject><subject>hepatitis C</subject><subject>Hepatitis C - complications</subject><subject>Humans</subject><subject>immunosuppressive agents</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Liver</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>1091-255X</issn><issn>1873-4626</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM1q3DAQgEVoyF_7BiEYCr3ZHUm2LF8CYWl-YKGhbKGnClkeJ1q8liPJgb31HfKGeZIq7EIhh-owGoZvfvgIOadQUKDi67p40CHMvmAAVQGiAAYH5ITKmuelYOJDyqGhOauqX8fkNIQ1AK2ByiNyTAXldSXpCfl9NUYbH7cbZ7YRs5vBtfNgx-xu7GYTrRuz1SN6PW2zVLzFSSfahmzx-ufl3oWUP2O2TMFnK6_HMA16jNkPNHayOMbwkRz2egj4af-fkZ_X31aL23z5_eZucbXMDZcy5owCauAthU62om9Ql12tZdu0ra5LKTnDqqZ9A5IbwZnpG93UDMpetI0uK-Bn5Mtu7uTd04whqo0NBod0Dro5KCGrKmkSCfz8Dly72Y_pNkUpZYzX6SWq3FHGuxA89mrydqP9VlFQb_bVWu3sqzf7CoRK9lPbxX743G6w-9e0152Ayx2AycWzRa-CSZ4Mdtajiapz9v8b_gIFtZlY</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Horton, Peter J.</creator><creator>Tchervenkov, Jean</creator><creator>Barkun, Jeff S.</creator><creator>Rochon, Caroline</creator><creator>Chaudhury, Prosanto K.</creator><creator>Znajda, Tammy L.</creator><creator>Martinie, John B.</creator><creator>Metrakos, Peter</creator><general>Elsevier Inc</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050901</creationdate><title>Antithymocyte Globulin Induction Therapy in Hepatitis C–Positive Liver Transplant Recipients</title><author>Horton, Peter J. ; Tchervenkov, Jean ; Barkun, Jeff S. ; Rochon, Caroline ; Chaudhury, Prosanto K. ; Znajda, Tammy L. ; Martinie, John B. ; Metrakos, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-210ea03b10d8b6f9ea4d7a8b9bba748832e571f9083c632cf9a97204f6b9a4503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alcohol Drinking</topic><topic>Antilymphocyte serum</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Cadaver</topic><topic>Cause of Death</topic><topic>Cytomegalovirus Infections - complications</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft Rejection - etiology</topic><topic>Graft Survival</topic><topic>Hepatitis B - complications</topic><topic>hepatitis C</topic><topic>Hepatitis C - complications</topic><topic>Humans</topic><topic>immunosuppressive agents</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Liver</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horton, Peter J.</creatorcontrib><creatorcontrib>Tchervenkov, Jean</creatorcontrib><creatorcontrib>Barkun, Jeff S.</creatorcontrib><creatorcontrib>Rochon, Caroline</creatorcontrib><creatorcontrib>Chaudhury, Prosanto K.</creatorcontrib><creatorcontrib>Znajda, Tammy L.</creatorcontrib><creatorcontrib>Martinie, John B.</creatorcontrib><creatorcontrib>Metrakos, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastrointestinal surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horton, Peter J.</au><au>Tchervenkov, Jean</au><au>Barkun, Jeff S.</au><au>Rochon, Caroline</au><au>Chaudhury, Prosanto K.</au><au>Znajda, Tammy L.</au><au>Martinie, John B.</au><au>Metrakos, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antithymocyte Globulin Induction Therapy in Hepatitis C–Positive Liver Transplant Recipients</atitle><jtitle>Journal of gastrointestinal surgery</jtitle><addtitle>J Gastrointest Surg</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>9</volume><issue>7</issue><spage>896</spage><epage>902</epage><pages>896-902</pages><issn>1091-255X</issn><eissn>1873-4626</eissn><abstract>It is unclear whether antithymocyte globulin (ATG) induction therapy in hepatitis C–positive (HCV-positive) liver transplant recipients influences the risk of developing recurrent HCV disease. Multiple acute rejection episodes and high-dose steroids and/or OKT3 used to treat acute rejection increase the risk of graft loss from HCV. We studied the impact of ATG induction on graft and patient survival in HCV-positive liver transplants performed since 1990. Recipients who died or lost their grafts within 1 month of transplantation were excluded. Second, third, and fourth grafts were excluded, as were patients with stage III or IV hepatocellular carcinoma. There were 443 cadaveric liver transplants in adult recipients, of whom 142 (32%) were HCV positive. The incidence of biopsy-proven acute rejection was less in patients who received ATG induction, 34.2% (ATG induction) versus 66.6% (no ATG induction) (
P ≤ .01). ATG induction did not influence the risk of graft loss from HCV-related disease (
P
=
.75). When only HCV-related graft loss was considered, 10-year graft survival for HCV-positive recipients was 74% (ATG induction) versus 68.2% (no ATG induction). Whether ATG induction was given or not had no significant impact on either overall graft survival (
P
=
.39) or patient survival (
P
=
.11) in HCV-positive recipients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16137581</pmid><doi>10.1016/j.gassur.2005.06.020</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1091-255X |
| ispartof | Journal of gastrointestinal surgery, 2005-09, Vol.9 (7), p.896-902 |
| issn | 1091-255X 1873-4626 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68550056 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Alcohol Drinking Antilymphocyte serum Antilymphocyte Serum - therapeutic use Cadaver Cause of Death Cytomegalovirus Infections - complications Female Follow-Up Studies Graft Rejection - etiology Graft Survival Hepatitis B - complications hepatitis C Hepatitis C - complications Humans immunosuppressive agents Immunosuppressive Agents - therapeutic use Liver Liver Transplantation Male Middle Aged Recurrence Risk Factors Survival Rate Transplants & implants Treatment Outcome |
| title | Antithymocyte Globulin Induction Therapy in Hepatitis C–Positive Liver Transplant Recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A27%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antithymocyte%20Globulin%20Induction%20Therapy%20in%20Hepatitis%20C%E2%80%93Positive%20Liver%20Transplant%20Recipients&rft.jtitle=Journal%20of%20gastrointestinal%20surgery&rft.au=Horton,%20Peter%20J.&rft.date=2005-09-01&rft.volume=9&rft.issue=7&rft.spage=896&rft.epage=902&rft.pages=896-902&rft.issn=1091-255X&rft.eissn=1873-4626&rft_id=info:doi/10.1016/j.gassur.2005.06.020&rft_dat=%3Cproquest_cross%3E68550056%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112237777&rft_id=info:pmid/16137581&rft_els_id=S1091255X05005378&rfr_iscdi=true |